Vertex Says CF Patients with Double F508del Mutation Showing Improvement in VX-809/Kalydeco Trial
May 23, 2012
Vertex Says CF Patients with Double F508del Mutation Showing Improvement in VX-809/Kalydeco Trial
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MDx/CDx Focus: EC Approves Kalydeco; Cabozantinib in PGx-Targeted NSCLC; Ponatinib, CDx FDA Filing
August 1, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: FDA Accepts Pfizer's Bosutinib NDA; Kalydeco Approval; AssureRx Credit Line; and more
February 1, 2012 / Pharmacogenomics Reporter - Vertex Completes NDA on CF Drug for G551D Mutation, Releases Data on Other Targeted CF Therapies
November 9, 2011 / Pharmacogenomics Reporter - Manchester Unites with NHS on New Genomic Medicine Center
May 20, 2013 / GenomeWeb Daily News - PGx Drugs Xalkori, Zelboraf Show Strong Growth in First Quarter of 2013
May 1, 2013 / Pharmacogenomics Reporter